Can a dissolving stent coating beat a permanent one for blocked arteries?

NCT ID NCT01516723

NEW Completed Disease control Sponsor: R&D Cardiologie Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This trial compares two types of drug-eluting stents—tiny mesh tubes that prop open arteries—in people with completely blocked coronary arteries. One stent uses a coating that dissolves over time (bioresorbable polymer) to release the drug sirolimus, while the other has a permanent coating that releases everolimus. The goal is to see which stent better keeps the artery open and reduces the chance of re-narrowing, measured by how much the vessel narrows again at 9 months. Participants are adults with a blocked artery that has been successfully reopened, and the study randomly assigns them to receive one of the two stents.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Two types of drug-eluting stents: a hybrid sirolimus-eluting stent with a bioresorbable polymer (ORSIRO) and an everolimus-eluting stent with a durable polymer (XIENCE PRIME), both used to reopen totally blocked coronary arteries.
What this could lead to: If the bioresorbable-polymer stent works as well or better, it could reduce the risk of late stent complications and improve long-term outcomes for people with completely blocked coronary arteries.
What could go wrong: This is a mid-sized trial, and the outcome is measured at 9 months—longer-term effects, such as very late stent thrombosis, may not be fully captured. Also, results may not apply to all patients with coronary artery disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease coronary stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE CORONARY DISEASE CORONARY STENOSIS

Contacts and locations

Locations

AMC

Amsterdam, Amsterdam, 1105AZ, Netherlands
AZ Middelheim

Antwerp, Antwerpen, 2020, Belgium
Catharina Ziekenhuis

Eindhoven, Eindhoven, 5602ZA, Netherlands
St Antonius Hospital

Nieuwegein, 3435CM, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.